What is the role of targeted agents in the treatment of lymphoblastic lymphoma?

Updated: Sep 10, 2019
  • Author: Joseph M Tuscano, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


With NOTCH1 being the major oncogene in T-ALL and with drugs available that can interfere with the activation of NOTCH1 by the gamma-secretase complex, a number of clinical trials have been initiated with gamma-secretase inhibitors (GSIs). However, these trials led to disappointing clinical results due to the dose-limiting toxicity and low response rates. [19] Promising responses to second generation GSIs have been reported and with milder toxicities. [20, 21]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!